Puberty mennorhagia 15 marks mbbs question answer in detail

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
I now have sufficient material from authoritative textbooks. Let me compile the comprehensive MBBS answer:

Puberty Menorrhagia — Detailed MBBS Answer (15 Marks)


Definition

Menorrhagia (now classified under Abnormal Uterine Bleeding — Heavy Menstrual Bleeding, AUB-HMB per FIGO PALM-COEIN 2011) is defined as excessive cyclic uterine bleeding with:
  • Blood loss >80 mL per menstrual cycle, or
  • Duration >7 days, occurring at regular intervals
Puberty menorrhagia refers specifically to abnormal heavy uterine bleeding occurring in adolescents around the time of menarche (the first menstrual period) and the first 2–3 years after it.
Normal menstrual blood loss is ≤30 mL; cycles normally last 4.5–8 days at intervals of 21–35 days.

Epidemiology

  • Abnormal vaginal bleeding affects 10–30% of women of reproductive age
  • Heavy menstrual bleeding is very common in adolescents, as most early post-menarchal cycles are anovulatory
  • Menstrual cycles remain anovulatory for an average of 18 months after menarche while the hypothalamic-pituitary-ovarian (HPO) axis matures
  • Up to 20–24% of adolescents with menorrhagia may have an undiagnosed coagulation disorder
  • Primary coagulation disorders account for up to 20% of acute uterine bleeding in adolescents

Etiology and Pathophysiology

Primary Cause — Anovulation (Most Common)

The central mechanism is immaturity of the HPO axis:
  1. At menarche, the hypothalamus and pituitary have not yet developed mature positive feedback to rising estrogen levels
  2. The midcycle LH surge fails to occur → no ovulation → no corpus luteum formation
  3. Without a corpus luteum, progesterone is not produced
  4. Unopposed estrogen continues to stimulate endometrial proliferation
  5. The thickened, fragile endometrium outgrows its blood supply, sheds irregularly, and bleeds heavily — estrogen breakthrough bleeding
  6. Without progesterone-induced prostaglandin F2α (which causes vasospasm and hemostasis), bleeding is prolonged

PALM-COEIN Classification (FIGO 2011)

Structural (PALM)Non-structural (COEIN)
PolypCoagulopathy ← important in adolescents
AdenomyosisOvulatory Dysfunction ← most common
LeiomyomaEndometrial
Malignancy/HyperplasiaIatrogenic
Not yet classified

Causes Specific to Puberty Menorrhagia

CategoryExamples
Anovulation (commonest)HPO axis immaturity
Coagulopathyvon Willebrand disease (most common bleeding disorder), immune thrombocytopenia (ITP), myeloproliferative disorders, platelet dysfunction
Endocrine disordersHypothyroidism (can cause both menorrhagia and precocious/delayed puberty), hyperprolactinemia, PCOS
IatrogenicExogenous hormones, OCPs
Pelvic infectionEndometritis, PID
StructuralRarely polyps or congenital anomalies
Pregnancy complicationsMust always be excluded

Clinical Features

History

  • Heavy menstrual flow — soaking >1 pad/tampon per hour for several consecutive hours (each pad absorbs ~20–30 mL)
  • Passage of blood clots (indicates rapid blood loss exceeding the fibrinolytic capacity)
  • Prolonged bleeding duration (>7 days)
  • Fatigue, pallor, breathlessness → symptoms of iron-deficiency anemia
  • Onset near/around menarche
  • Family history of bleeding disorders (screen for von Willebrand disease if: heavy bleeding since menarche, plus two of: bruising monthly, epistaxis monthly, frequent gum bleeding)
  • History of postpartum hemorrhage or surgical/dental bleeding in family members
  • Drug history: anticoagulants, SSRIs, herbal supplements (ginseng)

Symptoms to Elicit (Underlying Causes)

  • Weight gain, cold intolerance, constipation → hypothyroidism
  • Galactorrhea → hyperprolactinemia
  • Hirsutism, obesity → PCOS
  • Petechiae, purpura, mucosal bleeding → hematologic disorder

Physical Examination

  1. General: Pallor, tachycardia, hypotension (assess hemodynamic stability first)
  2. BMI: Obesity suggests PCOS
  3. Skin: Hirsutism (PCOS), petechiae/purpura (coagulopathy), acne
  4. Thyroid: Goiter (hypothyroidism)
  5. Galactorrhea: Squeeze for nipple discharge
  6. Pelvic examination (with chaperone):
    • Inspect vulva, perineum, urethra, perianal region
    • Speculum: visualize cervix and vaginal canal
    • Bimanual: uterine size, adnexal masses, tenderness
    • Note: In adolescents who are not sexually active, rectal exam may substitute bimanual exam

Investigations

Step 1 — Immediate (All Cases)

InvestigationRationale
Complete Blood Count (CBC)Anemia, thrombocytopenia
Blood group and cross-matchSevere/acute bleeding
Urine/serum βhCGExclude pregnancy (always first)
Coagulation profile (PT, aPTT, bleeding time)Screen for coagulopathy
von Willebrand disease panel (vWF antigen, vWF activity, Factor VIII)Indicated in adolescents with menorrhagia

Step 2 — Hormonal and Metabolic

InvestigationRationale
TSHHypothyroidism
ProlactinHyperprolactinemia
LH/FSH ratioPCOS (LH:FSH >2:1)
Androgens (testosterone, DHEAS)PCOS, adrenal hyperplasia
Fasting glucose/insulinPCOS/metabolic syndrome

Step 3 — Imaging

InvestigationRationale
Pelvic ultrasound (transvaginal or transabdominal)Uterine/ovarian anatomy, endometrial thickness, polyps, fibroids, ovarian cysts

Step 4 — If Indicated

  • Endometrial biopsy: In adolescents generally NOT required unless persistent AUB unresponsive to treatment; reserved for women >45 or those with risk factors for hyperplasia
  • Hysteroscopy: For structural lesions
  • Bone marrow biopsy: If myeloproliferative disorder suspected

Diagnosis

Diagnosis is primarily clinical, supported by investigations:
  • Heavy menstrual bleeding near menarche
  • Regular/irregular cycles (anovulatory cycles are often irregular)
  • Exclusion of pregnancy, structural causes, coagulopathy
  • Most cases = anovulatory AUB (HPO axis immaturity)

Differential Diagnosis

  1. Pregnancy complications (threatened/inevitable abortion, ectopic)
  2. Coagulation disorders (vWD, ITP)
  3. Hypothyroidism
  4. PCOS
  5. Pelvic infection / endometritis
  6. Cervical or vaginal trauma/foreign body
  7. Structural lesions (polyp, fibroid — rare at this age)

Management

Management depends on severity of bleeding and the underlying cause.

A. General Measures

  • Reassurance — explain the physiologic basis (HPO immaturity)
  • Correct iron deficiency anemia: oral ferrous sulfate 200 mg TDS
  • Monitor hemoglobin; transfuse if Hb <7 g/dL or hemodynamically unstable

B. Medical Management

1. Non-hormonal (for mild–moderate bleeding)

DrugMechanismDose
Tranexamic acid (FDA-approved for menorrhagia)Antifibrinolytic — inhibits plasminogen activator; reduces menstrual blood loss1–1.3 g IV (acute) or 1 g TID orally during menses
NSAIDs (mefenamic acid, ibuprofen)Inhibit prostaglandins → reduce blood loss; also analgesicMefenamic acid 500 mg TID from onset of menses

2. Hormonal Management (Mainstay in Adolescents)

DrugRegimenIndication
Combined Oral Contraceptive Pill (COCP) — monophasic1 pill TID for 7 days (acute), then maintenance 1/day for cycle controlAnovulatory AUB; not contraindicated in adolescents
Progestin alone (medroxyprogesterone acetate, norethisterone)Cyclic days 16–25 of cycleAnovulation, if estrogen contraindicated
Levonorgestrel IUS (Mirena)Delivers local progestin; reduces endometrial proliferationEffective long-term; may not be first choice in nulliparous adolescent
High-dose estrogenConjugated equine estrogen 25 mg IV q4h (max 6 doses)Acute severe bleeding to stop — promotes endometrial healing (use with antiemetic; NOT if VTE risk)
Note: High-dose IV estrogen in acute profuse bleeding followed by COCP for maintenance is the classic "stop the bleed" regimen in adolescents.

3. Management of Specific Causes

  • Hypothyroidism → Levothyroxine (bleeding resolves with thyroid correction)
  • vWD → DDAVP (desmopressin) or vWF concentrate; tranexamic acid adjunct
  • ITP → Corticosteroids, IV immunoglobulin, platelet transfusion if critical
  • PCOS → COCP + lifestyle modification; metformin

C. Surgical Management

Reserved for cases failing medical therapy:
ProcedureIndication
Dilation and Curettage (D&C)Diagnostic + therapeutic; provides temporary relief; NOT a definitive treatment
Endometrial ablationOlder adolescents who have completed family; 29% ultimately require hysterectomy
HysterectomyLast resort; only if all else fails and childbearing is not desired
D&C alone is NOT recommended as a sole treatment as it does not provide long-term control.

D. Management Algorithm Summary

Puberty Menorrhagia
       │
       ├── Hemodynamically UNSTABLE
       │        ├── IV access, resuscitation
       │        ├── High-dose IV conjugated estrogen OR
       │        │   IV tranexamic acid 1–1.3 g
       │        ├── High-dose COCP to stabilize
       │        └── Hematology/GYN consult; D&C if needed
       │
       └── Hemodynamically STABLE
                ├── Exclude pregnancy (βhCG)
                ├── Investigations: CBC, coagulation, TSH, vWD screen
                ├── Iron supplementation
                ├── Mild → NSAIDs + tranexamic acid
                ├── Moderate → Cyclic progestin or COCP
                └── Treat underlying cause

Complications

  1. Iron-deficiency anemia — most common complication
  2. Hypovolemic shock — in severe acute hemorrhage
  3. Psychological impact — school absence, social embarrassment, anxiety
  4. Infertility (if underlying PCOS or coagulopathy untreated)
  5. Complications of untreated hypothyroidism or PCOS

Prognosis

  • Excellent for anovulatory puberty menorrhagia — most cases resolve spontaneously as the HPO axis matures (within 2–3 years of menarche)
  • Cases with underlying coagulopathy (e.g., vWD) require long-term hematologic management but do well with targeted therapy
  • PCOS is a chronic condition requiring ongoing management

Key Points for MBBS Examination

PointFact
Most common causeAnovulation (HPO axis immaturity)
Most common coagulopathyvon Willebrand disease
Coagulopathy prevalenceUp to 20–24% of adolescent menorrhagia
Normal blood loss≤30 mL/cycle
Abnormal blood loss>80 mL/cycle
Duration of anovulatory cyclesAverage 18 months post-menarche
First investigationUrine βhCG (exclude pregnancy)
Gold standard classificationPALM-COEIN (FIGO 2011)
Medical treatment (acute, severe)IV conjugated estrogen + COCP; IV tranexamic acid
Mainstay outpatient treatmentCOCP or cyclic progestin
Obsolete term"Dysfunctional uterine bleeding" (replaced by AUB)

Sources: Textbook of Family Medicine 9e; Tintinalli's Emergency Medicine; Berek & Novak's Gynecology; Rosen's Emergency Medicine — all accessed via the Medical Textbook Library.
This is a shared conversation. Sign in to Orris to start your own chat.